Tosoh Bioscience, Inc.
$2.6M 9 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Cerus Corporation
Cerus Corporation reported $2,628,556.38 across General Payments, Research, and Ownership to 372 physicians and teaching hospitals across 463 transactions.
- $2.6M Top quartile payer
- All-tracks total
- 463 Above-median volume
- Transactions
- 372 Above-median reach
- Recipients
- +$74.6K
- General Payments vs PY2023
Cerus Corporation reported $2,628,556.38 across all CMS Open Payments tracks (General + Research + Ownership) to 372 physicians and teaching hospitals in Program Year 2024 - ranking #395 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $405,693.53, averaging $7.1K per recipient.
How Cerus Corporation's $2.6M all-tracks total breaks down
Cerus Corporation's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
31/100
Total payments
F
34/100
Transaction volume
F
13/100
Physician reach
F
13/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer cerus-corporation Cerus Corporation
$2.6M · #395/1,925 · 0.0% industry · PY2024
- TOT $2.6M
- RANK #395
- SHARE 0.0%
- TXN 463
- RCP 372
- CAT 5
- GEN $405.7K
- ΔGEN +$74.6K
- TOP1 38.9%
- PY 2024
Volume peers
Nearest volume peer: Tosoh Bioscience, Inc. ($2.6M)
Cerus Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Cerus Corporation's CMS-reported General Payments increased by $74.6K (+22.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CERUS CORPORATIONPY2023: CERUS CORPORATIONPY2024: Cerus Corporation. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $331,076.20
- PY2024
- $405,693.53
What the Data Shows for Cerus Corporation
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Cerus Corporation, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
29 transactions worth $256.2K make "Consulting Fee" the top general-payment category in the 5-category breakdown below, 63.2% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 5 types of general payments, Cerus Corporation's largest category was "Consulting Fee" at $256.2K - 63.2% of General Payments.
Cerus Corporation reports 5 general-payment categories - the top three are Consulting Fee (63.2%), Travel and Lodging (13.8%), and Honoraria (12.5%). The remaining 2 categories make up 10.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Cerus Corporation divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $256.2K | 29 | 63.2% |
| Travel and Lodging | $56.0K | 38 | 13.8% |
| Honoraria | $50.6K | 25 | 12.5% |
| Food and Beverage | $38.5K | 271 | 9.5% |
| Gift | $4.4K | 9 | 1.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $251,978.02 (62.1%) of $405,693.53 in this company's General Payments records across 173 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Cerus Corporation
The five named recipients with the highest reported General Payments from this company
- 1
Philip Spinella
$157,985.31 across 30 reported transactions
- 2
Hua Shan
$52,830.52 across 11 reported transactions
- 3
Scott Le Maire
$15,529.74 across 6 reported transactions
- 4
Majed Refaai
$13,183.32 across 5 reported transactions
- 5
Lucy Kornblith
$12,449.13 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Cerus Corporation ranks #395 of 1,925 by total payments (top 21% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #797 of 1,838 by HHI (top 43% most concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Ignite Orthopedics, LLC : $705.4K total payments, HHI 1790
- BioPro, Inc. : $101.9K total payments, HHI 1788
- Lazarus 3D : $1.2K total payments, HHI 1788
- exocad America, Inc. : $54.9K total payments, HHI 1781
- Citieffe, Inc. : $145.4K total payments, HHI 1775
- Diagnostica Stago, Inc : $49.4K total payments, HHI 1775
- Cerus Corporation (this company) : $405.7K total payments, HHI 1771
- Brixton Biosciences, Inc. : $36.4K total payments, HHI 1756
- Sysmex America, Inc. : $54.4K total payments, HHI 1755
- bluebird bio, Inc. : $208.3K total payments, HHI 1750
- Pfizer International LLC : $197.5K total payments, HHI 1747
- NextStep Arthropedix, LLC : $125.7K total payments, HHI 1747
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Cerus Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Cerus Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Cerus Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
Ardelyx, Inc.
$2.6M 42,247 recipients
Compare payment profiles
Global Blood Therapeutics, Inc.
$2.7M 0 recipients
Compare payment profiles
Acella Pharmaceuticals, LLC
$2.6M 1,941 recipients
Compare payment profiles
Vertical Orthopaedics, Inc.
$2.7M 19 recipients
Compare payment profiles
Calyxo, Inc.
$2.7M 1,299 recipients
Compare payment profiles
Put this to use
Cerus Corporation ranks #395 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Cerus Corporation sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Cerus Corporation. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.